Literature DB >> 19589431

The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy.

Barry J Maron1, Martin S Maron, E Douglas Wigle, Eugene Braunwald.   

Abstract

Dynamic obstruction to left ventricular (LV) outflow was recognized from the earliest (50 years ago) clinical descriptions of hypertrophic cardiomyopathy (HCM) and has proved to be a complex phenomenon unique in many respects, as well as arguably the most visible and well-known pathophysiologic component of this heterogeneous disease. Over the past 5 decades, the clinical significance attributable to dynamic LV outflow tract gradients in HCM has triggered a periodic and instructive debate. Nevertheless, only recently has evidence emerged from observational analyses in large patient cohorts that unequivocally supports subaortic pressure gradients (and obstruction) both as true impedance to LV outflow and independent determinants of disabling exertional symptoms and cardiovascular mortality. Furthermore, abolition of subaortic gradients by surgical myectomy (or percutaneous alcohol septal ablation) results in profound and consistent symptomatic benefit and restoration of quality of life, with myectomy providing a long-term survival similar to that observed in the general population. These findings resolve the long-festering controversy over the existence of obstruction in HCM and whether outflow gradients are clinically important elements of this complex disease. These data also underscore the important principle, particularly relevant to clinical practice, that heart failure due to LV outflow obstruction in HCM is mechanically reversible and amenable to invasive septal reduction therapy. Finally, the recent observation that the vast majority of patients with HCM have the propensity to develop outflow obstruction (either at rest or with exercise) underscores a return to the characterization of HCM in 1960 as a predominantly obstructive disease.

Entities:  

Mesh:

Year:  2009        PMID: 19589431     DOI: 10.1016/j.jacc.2008.11.069

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  49 in total

Review 1.  Paradoxical and bidirectional drug effects.

Authors:  Silas W Smith; Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

Review 2.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

3.  33-year-old man with syncope.

Authors:  Seth H Sheldon; Nicholas M Orme; Kyle W Klarich
Journal:  Mayo Clin Proc       Date:  2011-07       Impact factor: 7.616

Review 4.  Fluid dynamic aspects of ejection in hypertrophic cardiomyopathy.

Authors:  Ares Pasipoularides
Journal:  Hellenic J Cardiol       Date:  2011 Sep-Oct

5.  Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiac magnetic resonance.

Authors:  Bradley D Allen; Lubna Choudhury; Alex J Barker; Pim van Ooij; Jeremy D Collins; Robert O Bonow; James C Carr; Michael Markl
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-08-09       Impact factor: 6.875

Review 6.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

7.  Evidence for impaired left ventricular ejection in hypertrophic obstructive cardiomyopathy: dynamic aortic ejection flow velocity profile demonstrated by pulsed Doppler echocardiography.

Authors:  Yutaka Otsuji; Akira Kisanuki; Shinichi Minagoe; Chuwa Tei
Journal:  J Echocardiogr       Date:  2012-01-26

Review 8.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

9.  Preventing sudden cardiac death in athletes: in search of evidence-based, cost-effective screening.

Authors:  Paolo Angelini; Mladen I Vidovich; Christine E Lawless; Macarthur A Elayda; J Alberto Lopez; Dwayne Wolf; James T Willerson
Journal:  Tex Heart Inst J       Date:  2013

10.  [Magnetic resonance imaging of hypertrophic cardiomyopathy : evaluation of diastolic function].

Authors:  F Schwarz; F Schwab; B M Beckmann; F Schuessler; D Zinsser; T Gölz; S Kääb; M F Reiser; D Theisen
Journal:  Radiologe       Date:  2013-01       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.